A Case of Late Implantable Cardiac Device Infection with *Aspergillus* in an Immunocompetent Host

**Patient:** Female, 67

**Final Diagnosis:** Infected pacemaker device secondary to *Aspergillus fumigatus*

**Symptoms:** Swelling over the left pectoral region

**Medication:** Voriconazole

**Clinical Procedure:** Pacemaker explantation

**Specialty:** Cardiology

**Objective:** Unusual clinical course

**Background:** With the increasing use of cardiac implantable electronic devices (CIED), there has been an associated increase in rate of complications. Infection accounts for about 1% of these, of which only a handful were reported secondary to *Aspergillus fumigatus*. All of these were seen in chronically-ill patients with several co-morbid conditions within a few years of implantation. None have been reported in an otherwise immunocompetent patient at 7 years after CIED implantation.

**Case Report:** A 67-year-old woman with symptomatic sick sinus syndrome required a pacemaker 15 years ago with subsequent revision 7 years prior due to battery depletion. She now presented with a left pectoral non-tender mass that developed over several weeks. She denied history of recent fever, trauma, or infection. An elective pacemaker revision and pocket exploration led to the drainage of 150 cc of serosanguineous discharge from the pocket. She received peri-procedural prophylaxis with Vancomycin, but later, wound cultures grew *Aspergillus fumigatus*. She underwent complete removal of the pacemaker system along with a 6-week course of voriconazole and is doing well.

**Conclusions:** Even though *Staphylococcus aureus* causes most CIED infections, there should be a suspicion for fungal organisms, especially in culture-negative infections, in immunocompromised states like diabetes mellitus or with minimal improvement on antibiotics. If not treated appropriately, aspergillosis may have catastrophic outcomes, including endocarditis, often leading to death. Appropriate treatment should include immediate initiation of antifungals and removal of the CIED. It is still unclear why an immunocompetent patient developed aspergillosis, but appropriate management helped avoid a grave outcome.

**MeSH Keywords:** Aspergillosis • Cardiac Resynchronization Therapy Devices • Mycoses • Pacemaker, Artificial

**Full-text PDF:** [http://www.amjcaserep.com/abstract/index/idArt/893413](http://www.amjcaserep.com/abstract/index/idArt/893413)
Infections account for about 1% of the complications associated with the use of cardiovascular implantable electronic devices (CIED), in spite of aggressive precautions [1]. The most common organism implicated is *Staphylococcus aureus*, with 50% being MRSA (methicillin resistant *Staphylococcus aureus*) followed by *Escherichia coli* and *Staphylococcus epidermidis* [2]. Only about 2% of these are secondary to a fungal infection [3]. The majority of these latter cases were lead infections with a few complicated with endocarditis. Only 5 cases were reported who had a generator pocket infection [4–7]. Most commonly seen were the *Aspergillus* species with one case reporting Candida, but all of them had chronic disease which could have caused the patient to be vulnerable to a fungal infection. We report a patient with immunocompetent status having a pacemaker pocket infection with *Aspergillus*, after over 7-years post-implantation which was successfully treated with appropriate antifungals and removal of the entire pacing system.

**Discussion**

With the increasing use of cardiovascular implantable electrophysiological devices (CIED) there has also been a rise in the rate of associated complications. Most commonly seen are bleeding, infections, lead dislodgement, pneumothorax, cardiac perforation, and, rarely, death. Infection rates are variable, but there has been an increase in the recent incidence of infections, ranging from 1% to 7% [1]. In a prospective study [8] of over 1008 patients undergoing CIEDs at our facility, only 1.4% patients developed wound-culture-positive superficial infection, with the rate of bacteremia and pocket infection of only 0.1%. Despite sterile precautions and the use of antibiotic prophylaxis at the time of device placement or revision, the rate of device-related infections may have increased, according to reports from several national databases [3,9]. It is hypothesized that the rise in infection rates could be due to the older and sicker population that required the implantation of cardiac devices.

**Classifying**

- Infections after device implant can be classified into early and late based on the time since the implant (within 60 days or beyond) [2].
- They can also be considered in two categories:

**Pocket infections**

Deeper infections – which include device-related endocarditis.

- Alternatively, device infections may be classified by the mode of infection:

Primary infections – when the source of infection is from the device due to contamination at the time of implant.
Secondary infection – where the leads get infected due to bacteria from a different source and can also progress to pocket or generator infection.

- Source of infection can be exogenous (from infected devices) or endogenous.

In support of endogenous acquisition, an association has been noted between the presence of preaxillary skin flora and the pathogens isolated from pacemaker infection. Therefore, aggressive peri-operative wound care has shown to reduce the incidence of infections in patients undergoing CIED implants.

**Etiology**

Early infections are most commonly caused by *Staphylococcus aureus* [2] of which methicillin-resistant *Staphylococcus aureus* (MRSA) would account for about half. Late infections are most commonly by Streptococcus. *Corynebacterium* species, *Propionibacterium acnes*, Gram-negative bacilli including *Pseudomonas aeruginosa*, and *Candida* species account for a minority of CIED infections [2,4]. Fungi other than *Candida* and non-tuberculosis mycobacteria are rarely identified as pathogens in CIED infection with the incidence being less than 2% [3].

**Aspergillus**

*Aspergillus fumigatus* is a significant and potentially life-threatening fungus, seen especially in an immunocompromised host. It is particularly abundant in the air of buildings with deficient ventilation systems and near construction sites. It most commonly affects the respiratory tract, but other sites, including skin, have also been identified as portals of entry [4] and many times, the source of infection remains unknown [10].

Only a handful of cases have been reported with *Aspergillus* as the cause for CIED infections. One of the first cases reported was back in the 1980s and almost all of them in that era resulted in death with diagnosis being made post-mortem [5,11]. Commonly seen risk factors include immunosuppression, long-term antibiotic or corticosteroid use, diabetes mellitus, heart failure or chronic kidney disease, prolonged hospitalization or cardiothoracic surgery [12].

The majority of these cases have been seen with lead infections and endocarditis often with tricuspid valve vegetations [4]. An article published in 2007 [6] reviewed 15 cases of *Aspergillus* associated pacemaker and ICD infections, of which only two had pocket infections. So far only four cases have been reported in association with pacemaker pocket infection and all of these occurred either acutely or sub-acutely.

Pincus et al. [4] described a 54-year-old man who developed an infection at the pacemaker site just within a few days of having multiple procedures/revisions of the pacemaker. Even though he had no systemic signs of infection, the pacemaker site looked visibly infected with cultures of the pocket and lead eventually growing *Aspergillus fumigatus*. He was effectively treated with voriconazole and linezolid. In contrast, Izquierdo et al. [7] described two patients who developed pocket infections secondary to *A. fumigatus* but almost 1.5 to 2 years after device manipulation. Like Pincus et al., their cases also had risk factors like diabetes, but eventually did well with surgical and medical treatment. Cobo et al. [6] reported a 74-year-old woman presenting with pocket infection, which was later found to be from *Aspergillus fayus*. An Echocardiogram in addition showed vegetations in the cardiac leads. She also did well after removal of the pacemaker system and with anti-fungal therapy.

The four cases described above had multiple manipulations of the pacemaker device and also had chronic disease like diabetes, which rendered the patient vulnerable to fungal infection. In addition, the time since implant to presentation varied from a few weeks to two years. In contrast, our patient had no chronic disease, nor any malignancy. Extensive investigations were done to rule out any occult malignancy and even HIV was tested. There was no history suggestive of exposure to mold either. She was healthy and was immunocompetent, yet she developed *Aspergillus fumigatus* infection, that too almost seven years after pacemaker implant making the source of infection, the pacemaker generator, less likely.

If not diagnosed early and treated appropriately, fungal infections are associated with a high mortality because of lead involvement and thrombus formation. Pocket infections can be identified by cultures. But most often, they have a prolonged incubation period ranging anywhere from one day to two weeks. Diagnosing fungal endocarditis remains elusive because of negative blood cultures [13,14]. It has been reported that they are positive only in about 11% of cases [15], thus accounting for the high mortality. Once there is suspicion of *Aspergillus infection*, or when confirmed, immediate anti-fungal therapy should be initiated. As mentioned above, as it most often involves the leads and endocarditis, an echocardiogram is almost always recommended to evaluate the presence of lead and/or valve vegetations. Transthoracic echocardiograms may not be solely enough to identify the vegetations or thrombus so a transesophageal echocardiogram is suggested [13].

Treatment includes appropriate anti-fungal therapy, even before confirming the diagnosis with culture results. Anti-fungal agents like Amphotericin B, flucytosine and itraconazole have been used, but Voriconazole remains the first choice [10]. Additionally, removal of the CIED system is strongly...
recommended, because of the possibility of large intravascular vegetations, for which plain medical therapy may be insufficient [13]. The procedure must be performed with caution in patients who are dependent on the pacemaker or ICD as mortality can be high, but patients tend to do well.

Conclusions

Even though the most commonly seen pathogens for CIED infections are *Staphylococcus aureus* and *Streptococcus*, fungal infections, especially Aspergillus, have been found to have occurred only acutely or sub-acutely. To the best of our knowledge, there have been no cases of *Aspergillus* infection reported beyond two years after device implantation or manipulation. In addition, fungal infections were only found to have occurred in patients with kidney disease, diabetes, or in an immunocompromised state. We report for the first time a CIED pocket infection by *Aspergillus* almost 7 years after device manipulation in a patient with no risk factors which is an unusual presentation of an unusual complication. So far, in a follow-up period of nine months, we have yet to find a reason why she developed a fungal infection, but she responded well to treatment and has been doing well.

We should be aware that *Aspergillus* can be found anywhere and can cause early or delayed infection, involving the CIED pocket, leads, or both. Although usually associated with an immunocompromised host, it should also be suspected in immunocompetent patients, especially when there is minimal improvement with conventional therapy alone.

Conflict of interest

The authors have no conflict of interest to report. There is no source of funding for this report.

References:

1. Chu JD, Wilkoff BL, Lee I et al: Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med, 2000; 133: 604–8
2. Dunn CJ, Ruder M, Deresinski SC: *Aspergillus fumigatus* infection of an automatic internal cardiac defibrillator. Pacing Clin Electrophysiol, 1996; 19: 2156–57
3. Baddour LM, Epstein AE, Erickson CC et al: Update on cardiovascular implantable electronic device infections and their management. a scientific statement from the American Heart Association. Endorsed by the Heart Rhythm Society. Circulation, 2010; 121: 458–77
4. Pincus J, Jahng M, Massie L, Lee SA: Early *Aspergillus* pacemaker pocket infection: Case and review. Med Mycol Case Rep, 2012; 1(1): 32–34
5. Moorman JR, Steenbergen C, Durack DT: *Aspergillus fumigatus* infection of a permanent ventricular pacing lead. Pacing Clin Electrophysiol, 1984; 7: 361–64
6. Cobo M, Ramos A, Toquero J et al: *Aspergillus* infection of implantable cardioverter-defibrillators and pacemakers: case report and literature review. Eur J Clin Microbiol Infect Dis, 2007; 26(5): 357–61
7. Izquierdo R, Llorente C, Mayo J et al: Pacemaker infection due to *Aspergillus*: report of two cases and literature review. Clin Cardiol, 2005; 28(1): 36–38
8. Khalighi K, Aung TT, Elmi F: The Role of prophylaxis topical antibiotics in cardiac device implantation. Pacing Clin Electrophysiol, 2014; 37(3): 304–11
9. Baddour LM, Cha Y, Wilson WR: Infections of cardiovascular implantable electronic devices. N Engl J Med, 2012; 367: 842–49
10. Marchena Yglesias PI, Nieto Rodriguez JA, Arranz Garcia G et al: Pacemaker lead infection caused by *Aspergillus fumigatus*. Eur J Intern Med, 2006; 17: 209–10
11. Gannon BR, Leong R, Childs TJ et al: *Aspergillus fumigatus* pacemaker endocarditis: a rare complication of pacemaker implantation. Pathology, Research and Practice, 2004; 200: 641
12. Leong R, Gannon BR, Childs TJ et al: *Aspergillus fumigatus* pacemaker lead endocarditis: a case report and review of the literature. Can J Cardiol, 2006; 22(4): 337–40
13. Cook RJ, Orszulak TA, Nikom VT et al: *Aspergillus* infection of implantable cardioverter-defibrillator. Mayo Clin Proc, 2004; 79: 549–52
14. Kramer L, Corona RR, Sheff D, Eisenberg ES: Disseminated aspergillosis and pacemaker endocarditis. Pacing Clin Electrophysiol, 1985; 8: 225–29
15. Pillai J, Mubeen M, Chaudhari A, Dalma B: *Aspergillus* pacemaker lead endocarditis. Asian Cardiovasc Thorac Ann, 2012; 21(2): 211–14